Welcome to our dedicated page for Strata Critical Medical news (Ticker: SRTA), a resource for investors and traders seeking the latest updates and insights on Strata Critical Medical stock.
News about Strata Critical Medical, Inc. (Nasdaq: SRTA) focuses on its role in time-critical logistics and medical services for the U.S. healthcare and organ transplant industries. Company announcements highlight developments in its organ transport network, integrated organ recovery platform and specialized clinical services delivered through brands such as Trinity Medical Solutions and Keystone Perfusion.
Investors following SRTA news can expect updates on topics the company emphasizes in its communications, including acquisition activity, integration milestones and strategic shifts such as the divestiture of its Passenger business and rebranding from Blade Air Mobility to Strata Critical Medical. Press releases also cover events like Investor Day presentations at the Nasdaq MarketSite and conference appearances, where management discusses its financial framework and business strategy.
Operational news often addresses performance in air and ground logistics for organ transport, growth in organ placement services and expansion of normothermic regional perfusion and perfusion staffing offerings. The company’s updates may also describe how acquisitions like Keystone Perfusion contribute to creating a full-service organ transplant and cardiovascular care platform, as well as efforts to broaden services into other medical sectors.
For readers tracking SRTA, this news stream offers insight into how Strata is shaping its organ logistics and medical services platform, how it characterizes its market position and risk factors, and how management presents its non-GAAP metrics and financial outlook. Regularly reviewing these items can help observers understand the company’s evolving focus on transplant logistics, clinical services and acquisition-led growth within the U.S. healthcare ecosystem.
Strata Critical Medical (Nasdaq: SRTA) completed the all-cash acquisition of Louisville Perfusion Services, a regional perfusion and blood management provider in Kentucky. The deal totals about $16 million upfront plus up to $4 million in performance-based consideration.
LPS is expected to generate about $10 million revenue and $3 million Adjusted EBITDA in 2026. The acquisition expands Strata’s cardiac perfusion platform, which serves more than 275 hospitals, and enhances support for organ transplant programs, ECMO services, and regional coverage in the Midwest and Southern United States.
Strata Critical Medical (Nasdaq: SRTA) announced that its Public Warrants (Nasdaq: SRTAW) and Private Placement Warrants expired at 5:00 p.m. Eastern Time on May 7, 2026 in accordance with their original terms. The expiration was announced by the company on that date.
Strata Critical Medical (Nasdaq: SRTA) reported Q1 2026 continuing-operations results: revenue $67.4M (+87.4% YoY), logistics revenue $47.6M (+32.4% YoY), total gross profit $14.1M (+100.2% YoY), and net income from continuing operations $2.4M. Adjusted EBITDA was $6.4M. Company completed bolt-on acquisition of Ohio Valley Perfusion Associates and reiterated 2026 guidance: revenue $260–275M, Adj. EBITDA $29–33M, and free cash flow $15–22M.
Strata (Nasdaq: SRTA) completed the acquisition of Ohio Valley Perfusion Associates (OVPA), a regional perfusion services provider in Ohio and Pennsylvania, for an approximate purchase price of $1 million.
OVPA brings a team of eight certified clinicians and services including ECMO, autotransfusion and organ recovery, and the deal was described as a mid-single-digit EBITDA multiple consistent with Strata's M&A strategy.
Strata Critical Medical (Nasdaq: SRTA) will release financial results for the first quarter ended March 31, 2026 on Wednesday, May 6, 2026 before market open. The company will host a conference call the same day at 8:00 AM ET to discuss results and answer questions.
Hosts will be Co-CEOs Melissa Tomkiel and Will Heyburn. Investors can register to join live and receive dial-in/PIN; an audio-only webcast will be available on the investor website and a replay will be accessible for one year.
Strata Critical Medical (NASDAQ: SRTA) will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 1:30 pm ET. A live webcast will be available and a replay will be posted on the company’s investor relations site shortly after the presentation.
Strata Critical Medical (Nasdaq: SRTA) reported Q4 2025 revenue of $66.8 million, up 83.5% year-over-year, and full-year 2025 revenue of $197.1 million. GAAP net loss from continuing operations for FY2025 was $20.1 million. Adjusted EBITDA for FY2025 was $14.1 million, above guidance. The company raised 2026 guidance to $260–$275 million revenue and $29–$33 million Adjusted EBITDA, ended FY2025 with $61.2 million cash, and closed a $30 million undrawn asset-backed facility.
Strata Critical Medical (Nasdaq: SRTA) will release fourth-quarter 2025 financial results on March 3, 2026 before the market opens and will host a conference call at 8:00 am Eastern Time the same day.
The call will be hosted by Will Heyburn (Co-CEO and CFO) and Melissa Tomkiel (Co-CEO and General Counsel), include a Q&A session, and require registration to receive dial-in details and a unique PIN. An audio-only webcast will be available on the company investor relations site and a replay will remain available for one year.
Strata (Nasdaq: SRTA) entered a secured, asset-based revolving credit agreement with JPMorgan Chase for up to $30.0 million, with an accordion to $50.0 million subject to conditions. The ABL Facility was undrawn at closing and will support future acquisitions. Owned aircraft are excluded from the collateral package and remain unencumbered, preserving financing optionality. Company executives said the facility improves capital efficiency and enables continued tuck-in acquisition execution in the clinical perfusion and organ transplant logistics space.
Strata Critical Medical (NASDAQ:SRTA) appointed Will Cook to its Board of Directors, effective December 3, 2025. Mr. Cook also joins the Compensation and Nominating and Corporate Governance Committees. He currently serves as President and CEO of Vail Health and previously led University of Colorado Hospital and held senior roles at UPMC and Johns Hopkins Health System. Strata said Cook’s healthcare leadership and industry relationships will support scaling its end-to-end organ recovery and logistics platform and advancing its mission to increase organs available for transplant.
Mr. Cook holds a master’s in health administration from Washington University School of Medicine and a BA in business administration from Texas A&M University.